Article
SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.
Journal of psychiatric research - 1 Feb 2015
Yeh Yi-Wei, Chen Cheng-Jueng, Jang Fong-Lin, Kuo Shin-Chang, Chen Chun-Yen, Liang Chih-Sung, Ho Pei-Shen, Yen Che-Hung, Shyu Jia-Fwu, Wan Fang-Jung, Lu Ru-Band, Huang San-Yuan
Abstract excerpt
OBJECTIVE: Venlafaxine, an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) type, is used to treat patients with major depressive disorder (MDD). Much evidence suggests that genetic polymorphisms may modulate serotonergic and noradrenergic function, thereby affecting the treatment efficacy of venlafaxine. The aim of this study was to examine whether polymorphisms in the norepinephrine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
